Revolutionary New Drugs (Ozempic, Wegovy) Treat Obesity, Diabetes and Addiction

Weight loss products and services constitute a multi-billion-dollar industry worldwide, but the money expended often leads to disappointing results. In the U.S., for example, the Centers for Disease Control (CDC) estimated that 41.9% of all adults over the age of 20 were obese during the 2017-2020 period. (Obese indicates a body mass index. or BMI, of 30 or more, compared a range of 18.5 to 24.9 BMI for normal weight bodies, depending on height and gender.)

Weight loss, particularly for the obese, may well provide the next massive, worldwide revenues boost for the pharmaceuticals industry. Earlier drugs in this channel work by reducing the absorption of food in the digestive tract. The previous generation of drugs include Saxenda from Novo Nordisk; Contrave, a combination of bupropion-naltrexone from Orexigen and Takeda; and Alli from Roche’s Xenical.

However, there are exciting next-generation drugs which show tremendous results in treating obesity and other conditions. They cause the patient’s appetite to diminish, thus lowering the intake of calories. They also can lead to a reduction in certain unhealthy behaviors, leading to less smoking of cigarettes and drinking of alcohol. The key is the use of these drugs to act as a “GLP-1 receptor agonist.” That is, they work by acting like a hormone that occurs naturally, known as GLP-1. (GLP stands for glucagon-like peptide.) The result is an increase in the feeling of being full and a corresponding reduction in appetite. For example, a person may feel quite full and satisfied with a small portion of pasta while on the drugs, who in the past might have had a compulsion to eat two or three large servings.

Importantly, these drugs are also known to be effective in treatment of type 2 diabetes (GLP-1 receptors are also involved in the release of insulin), and they show promise in helping patients with heart, kidney and liver diseases, sleep apnea, arthritis, Alzheimer’s disease and alcoholism or drug addiction. While many patients have achieved very significant weight loss with the drugs, they do have some drawbacks. They are expensive, but prices have been reduced significantly from original levels. Eli Lilly and Novo Nordisk both offer direct-to-consumer prices for their respective weight loss drugs Zepbound and Wegovy. Monthly cost by 2026 could be as little as $299 for the lowest level dosage, and $499 for high dosage.

Original versions required injections, but the newest versions are in pill form, greatly enhancing their appeal to people who do not want to receive (or give themselves) shots. Wegovy became available in pill form as of January 2026, while Eli Lilly’s Foundayo weight-loss pill became available in April 2026. Both are priced for a starting dose of $149 per month.

Side effects can include gastrointestinal problems such as vomiting and nausea. These limitations have to be considered alongside the fact that obesity is a condition that can lead to massive health complications and chronic diseases, including cardiovascular disease, diabetes, joint problems and many other life-limiting or life-threatening conditions. In addition, such conditions are extremely expensive to combat. In 2020, the Milken Institute, a non-profit group focused on advanced pharmaceuticals and health care research, estimated the combined economic and social impact of obesity (including such factors as missed days at work and reduced household income), to be $1.4 trillion yearly in the U.S. alone. A Swedish study found that people who are obese are three times more likely to receive disability payments and have twice as many sick days as non-obese people.

Breakthrough Obesity Drugs Wegovy, Zepbound and Ozempic

The drugs which have received FDA approval for obesity therapy include Novo Nordisk’s Semaglutide (under the brand name Wegovy). (This firm’s Ozempic was approved as a drug for Type 2 Diabetes but was also used by some obesity patients.) Tirzepatide (under the brand name Mounjaro) was approved as a diabetes drug but was used by many patients as a weight loss drug. A newer drug specifically for weight loss users is obesity-specific, called Zepbound, which was released in December 2023. Both Mounjaro and Zepbound are from Eli Lilly.

Various estimates place the global annual market for these GLP-1 drugs at $50 billion to $100 billion, making this field of extreme interest to pharmaceutical manufacturers, and positioning these treatments to be among the highest grossing drugs in history. The fact that ancillary benefits to the resulting weight loss are being proven, such as the reduction of stroke risk, provide even more potential to this market. Also, of great importance is the fact that these GLP-1 agonists may have tremendous promise in the control of compulsive disorders or serious addictions, such as alcohol or drugs.

Zepbound combines GLP-1 therapy with a gut hormone called glucose-dependent insulinotropic polypeptide (GIP), in order to help lower blood sugar and possibly increase metabolism. Trial data has been extremely supportive. One trial found that Zepbound helped patients to lose up to nearly 21% of their weight in 72 weeks, while Wegovy achieved nearly 15% at 68 weeks. Eli Lilly is also experimenting with adding glucagon to Zepbound, a hormone that can increase the number of calories that are burned. In one study, this triple combination enabled patients to lose almost 33% of their weight in 48 weeks.

While the drugs are expensive, they can prevent or greatly aid a wide variety of ailments and be vastly less costly that treatment surgeries and other therapies for chronic diseases. Some major insurers agree to cover GLP-1s for certain patients, but coverage has generally been restrictive, especially in the early years of the drugs’ launch. Meanwhile, demand has been so high that manufacturers initially had difficulty in maintaining sufficient supply. (Novo Nordisk acquired a New Jersey-based contract manufacturer called Catalent, Inc. in early 2024, significantly expanding its capacity

Patients in general are having great initial success with these drugs, reporting weight loss, fewer food cravings and significantly greater ease in feeling full after much smaller amounts of food. The future is very likely extremely bright for this sector, particularly when you consider the widespread incidence of obesity and the numerous, devasting diseases fueled by too much weight, including heart problems and diabetes. Nonetheless, patients who want lasting success may need to change their eating habits permanently or resign themselves to long-term usage of the drugs.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum.

Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum.

Become a Plunkett Research Online subscriber to gain unlimited access to our massive amount of vital industry data and market research.

✔ 100,000 Industry Statistics
✔ 500 Industries Analyzed for Market Size, Profits and Forecasts
✔ 150,000 Industry Executives Profiled
✔ 25,000 Companies Profiled, Ranked and Analyzed
✔ 1,000 Vital Trends Analyzed, totaling 1,000,000 words

Learn More

Revolutionary New Drugs (Ozempic, Wegovy) Treat Obesity, Diabetes and Addiction, Business and Industry Trends Analysis

A Representative List of Organizations that Have Used our Research and Products:

How to access Plunkett Research data.

What data challenge can we help you solve today?

Take a Tour

Contact

Testimonials